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Objective 
 Is there an ethnic disparity regarding the effect of  








β2-Agonists and Electrolyte 
Abnormalities 
 Potassium 
 Hypokalemia through increased cellular uptake 
 Glucose 
 Gluconeogenesis 
 Phosphate  
 Hypophosphatemia may be associated with 
ventilatory failure 
 Bicarbonate 







   
Ethnic Differences in Asthma 
 Higher morbidity and mortality in African Americans 
compared to Caucasians with asthma 
 Higher rates of  ED visits (350%) and hospitalizations 
(240%) 
 Reports of  interethnic differences in β2 treatment for 
acute asthma 
 SABA overuse and tolerance mechanism 
 Genetic differences at β2-receptor  
Study Methods 
MN-221 Trial 
 Sub-group analysis of  
large,  multi-center RCT 
evaluating a novel IV β2-
agonist for acute asthma 
exacerbation 
Select Exclusion Criteria 
 <18 and >55 years old 
 At risk for increased β1 response  
 Significant smoking history 
 COPD, or other chronic lung 




 Serum Mg, K, bicarbonate, and 
glucose were measured at 
“baseline” and “1.25hrs post-
baseline” 
  70 placebo subjects with plasma 




 Percent of  lab values outside 
normal range 





 43 African-Americans and 27 Caucasians 
 Significant correlations observed in 4/5 measures, all ethnic specific 
 Largest effect size with potassium and bicarbonate 
 Smaller effect size with magnesium and glucose 
 No effect with Phosphate, however large % low values 
Correlation Results 
Pearson r [95% CI] Total albuterol: 
Caucasians 
Total albuterol: 
African-Americans p value, R2 
Magnesium (mEq/L) 
-0.15 [-0.43, -0.15] 0.36 [0.13, 0.56] 
p= 0.32 p<0.01*, 0.13 
Potassium (mmol/L) 
-0.55 [-0.7, -0.31] -0.08 [-0.31, -0.14] 
p< 0.01*, 0.31 p=0.44 
Glucose (mg/dL) 
0.34 [0.07, 0.56] 0.10 [-0.11, 0.32] 
p=0.015*, 0.11 p=0.33 
Phosphate (mg/dL) 
-0.07 [-0.35, 0.21] 0.15 [-0.07, 0.36] 
p= 0.62 p= 0.17 
Bicarbonate (mmol/L 
-0.55 [-0.72, -0.32] -0.15 [-0.35, 0.07] 
p<0.01*, 0.30 p= 0.18 
Metabolic Abnormalities 
Value 
 [Lab Cut-Off] 
Median [IQR] N (%) AA ONR N (%) CA ONR 
Potassium   
[<3.6] mmol/L 
 
3.8  [3.5-4.1] 
  
14 (32.5%) 11 (46%) 
Magnesium  
 [>2.1]  mEq/L 
 
1.7  [1.5-1.8] 
  
3 (8.8%) 0 (0%) 
Phosphate  
[<2.4]  mg/dL 
 
2.7  [2.3-3.2] 
  
17 (40.5%) 10 (40%) 
Bicarbonate  
[<20]  mEq/L 
 
22  [20-24] 
  






22 (51%) 11 (42%) 
Conclusions 
 Ethnic-specific correlations between plasma albuterol and 
serum K, Bicarb, Mg, and Glu. 
 Specific to Caucasian population: 
 Sig negative correlation with K and Bicarb 
 Sig positive correlation with Glucose 
 Specific to African American population: 
 Sig positive correlation with Mg 
 High % hypophosphatemia observed for both populations 
Potential Clinical Implications 
 When repeated β2-agonist treatments given for acute asthma, 
closer ED monitoring may be required for: 
 Low K, low Bicarb and high Glucose in Caucasians 
 High magnesium in African Americans 
 Future research implications 
 These data suggest that combining ethnic groups may mask 




 Clinical relevance depends on magnitude of  change—
generally small effect size observed 





 Exclusion Criteria 
• Administration of  parenteral (intravenous or subcutaneous) beta agonist within 6 hours prior to 
randomization. 
• A current or prior diagnosis or suspected diagnosis of  COPD or other chronic lung disease other 
than asthma, the presence of  pneumonia, or presence of  significant other respiratory dysfunction 
such as pneumothorax, pneumomediastinum, or pulmonary edema. 
• Known or suspected vocal cord dysfunction syndrome or the presence of  aspirated foreign body 
(known or suspected). 
• History of  any current clinical evidence suggesting cardiomyopathy or congestive heart failure, 
history or presence of  tachyarrhythmia, with the exception of  sinus tachycardia, or a heart rate ≥ 140 
bpm. 
• Hypokalemia, defined as potassium level ≤ 2.8 mEq/L obtained at Screening. 
• Significant cardiac, renal, hepatic, endocrine, metabolic, neurologic or other systemic disease. 
• Self-reported history of  greater than 15 packer year smoking history. 
• Fever ≥ 102.0 ˚F (38.9˚C). 
• Uncontrolled hypertension defined as blood pressure ≥ 170/100 mm Hg. 
• Need for immediate intubation, mechanical ventilation, or non-invasive positive pressure ventilation 
as determined by the Investigator. 
• Pregnant or lactating females. 
• Participating in another clinical study with an investigational drug within 30 days of  randomization. 
• Positive urine drug screen for cocaine, methamphetamine or PCP. 
• Any subject with a known allergy components of  the MN-221 drug product or other beta agonists. 
• Previous exposure to MN-221 
• Use of  theophylline, beta blockers, diuretics, digoxin, MAO inhibitors, or tricyclic antidepressants, 
within 2 weeks prior to randomization.  
Plasma/Nebulized Albuterol Plasma Albuterol Mean  Nebulized Dose 
(mg) 
Total (R+S) 7.0 ng/mL 12.1 mg 
Plasma/ Nebulized 
Albuterol Correlation 
